Advertisement

Japanese Journal of Radiology

, Volume 32, Issue 11, pp 644–649 | Cite as

Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B)

  • Koichiro YamakadoEmail author
  • Shiro Miyayama
  • Shozo Hirota
  • Kimiyoshi Mizunuma
  • Kenji Nakamura
  • Yoshitaka Inaba
  • Satoshi Yamamoto
  • Kunihiro Matsuo
  • Norifumi Nishida
  • Takeshi Aramaki
  • Hiroshi Anai
  • Shinichi Kora
  • Shigeo Oikawa
  • Ken Watanabe
  • Taku Yasumoto
  • Kinya Furuichi
  • Masato Yamaguchi
Original Article

Abstract

Purpose

Retrospective evaluation of intermediate-stage hepatocellular carcinoma (HCC) patient survival after undergoing chemoembolization based on the Child-Pugh score.

Materials and methods

Data of intermediate-stage HCC patients undergoing chemoembolization were gathered from 43 centers in Japan. Overall survival rates were compared with Child-Pugh scores.

Results

Of the 329 patients examined in this study, Child-Pugh scores were 5 (CP-5) in 136 patients (41.3 %), 6 (CP-6) in 101 patients (30.7 %), 7 (CP-7) in 58 (17.7 %), 8 (CP-8) in 22 (6.7 %), and 9 (CP-9) in 12 (3.6 %). Two-year survival rates were 77.5 % in CP-5 patients (p = 0.047 vs. CP-6), 65.1 % in CP-6 patients (p = 0.038 vs. CP-7), 51.3 % in CP-7 patients (p = 0.30 vs. CP-8, p = 0.034 vs. CP-9), 50.3 % in CP-8 patients (p = 0.0065 vs. CP-9), and 16.7 % in CP-9 patients. Two-year survival rates were 77.2 % in 139 patients meeting the 4 tumors of 7 cm criterion with Child-Pugh class A (B1) (p < 0.0001 vs. B2), 59.5 % in 178 patients other than B1 and B3 (B2) (p = 0.0014 vs. B3), and 16.7 % in 12 patients with Child-Pugh score 9 (B3).

Conclusion

The Child-Pugh score is a useful prognostic factor to stratify intermediate-stage HCC patients.

Keywords

Hepatocellular carcinoma Chemoembolization Child-Pugh score Prognosis Stage 

Notes

Acknowledgments

We thank the following institutions and doctors for supporting this study: (1) Okitama Public General Hospital, Department of Radiology, Hitoshi Ito, MD; (2) Toho University Omori Hospital, Department of Department of Gastroenterology and Hepatology, Manabu Watanabe, MD; (3) National Center for Global Health and Medicine, Department of Radiology, KanehiroHasuo, MD; (4) Tokai University, Department of Radiology, Takeshi Hashimoto, MD; (5) Yamanashi University, Department of Radiology, Hiroki Okada, MD; (6) Shinshu University, Department of Radiology, Kazuhiko Ueda, MD; (7) Kouseiren Takaoka Hospital, Department of Radiology, Koji Nobata, MD; (8) Ishikawa Prefectural Central Hospital, Department of Radiology, Takeshi Kobayashi, MD; (9) Hamamatsu University School of Medicine, Department of Radiology, Mika Kamiya, MD; (10) Nagoya City University, Department of Radiology, Masashi Shimohira, MD; (11) Aichi Medical University, Department of Radiology, Seiji Kamei, MD; (12) Shiga University of Medical Science, Department of Radiology, Norihisa Nitta, MD; (13) Kohka Public Hospital, Department of Radiology, Michio Yamasaki, MD; (14) Japanese Red Cross Kobe Hospital, Department of Radiology, Koji Sugimoto, MD; (15) Nishi-Kobe Medical Center, Department of Radiology, YoichiroKuwata,MD; (16) Wakayama Medical University, Department of Radiology, Nobuyuki Kawai, MD; (17) Hiroshima University, Department of Radiology, Hideaki Kakizawa, MD; (18) Chugoku Rosai Hospital, Department of Radiology, Akira Naito, MD; (19) Tottori University, Department of Radiology, Toshio Kamino, MD; (20) Shimane University, Department of Radiology, Masakatsu Tsurusaki, MD; (21) Oita University, Department of Radiology, Hiromu Mori, MD; (22) Kumamoto University, Department of Radiology, Osamu Ikeda, MD; (23) Kagoshima University, Department of Radiology, Yasutaka Baba, MD; (24) Kanazawa University, Department of Radiology, Tetsuya Minami, MD; (25) Hokkaido University, Department of Radiology, Daisuke Abo, MD; (26) Okayama University, Department of Radiology, Hideo Gobara, MD; (27) Osaka University, Department of Radiology, Keigo Osuga, MD; (28) National Cancer Center, Department of Diagnostic Radiology, Yoshito Takeuchi; (29) Teikyo University, Department of Radiology, Hiroshi Kotake, MD; (30) Kyoto Second Red Cross Hospital, Department of Radiology, Hiroyuki Morishita, MD; (31) Kochi Health Science Center, Department of Radiology, Yasuhiro Hata, MD; (32) Nanbu Medical Center, Department of Radiology, Fumikiyo Ganaha, MD; (33) Keio University, Department of Diagnostic Radiology, Sachio Kuribayashi, MD.

Conflict of interest

There are no conflicts of interest to disclose from any of the authors.

References

  1. 1.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  2. 2.
    de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.PubMedCrossRefGoogle Scholar
  3. 3.
    Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–59.PubMedGoogle Scholar
  4. 4.
    Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Llovet JM, Real MI, Montan X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014;32:260–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Piscaglia F, Terzi E, Cucchetti A, Trimarchi C, Granito A, Leoni S, et al. Treatment of hepatocellular carcinoma in Child-Pugh B patients. Dig Liver Dis. 2013;45:852–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radiol. 2012;30:560–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona clinic liver cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, et al. Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study. World J Hepatol. 2012;27(4):256–61.CrossRefGoogle Scholar

Copyright information

© Japan Radiological Society 2014

Authors and Affiliations

  • Koichiro Yamakado
    • 1
    Email author
  • Shiro Miyayama
    • 2
  • Shozo Hirota
    • 3
  • Kimiyoshi Mizunuma
    • 4
  • Kenji Nakamura
    • 5
  • Yoshitaka Inaba
    • 6
  • Satoshi Yamamoto
    • 3
  • Kunihiro Matsuo
    • 7
  • Norifumi Nishida
    • 8
  • Takeshi Aramaki
    • 9
  • Hiroshi Anai
    • 10
  • Shinichi Kora
    • 11
  • Shigeo Oikawa
    • 12
  • Ken Watanabe
    • 13
  • Taku Yasumoto
    • 14
  • Kinya Furuichi
    • 15
  • Masato Yamaguchi
    • 16
  1. 1.Department of Interventional Radiology, School of MedicineMie UniversityTsuJapan
  2. 2.Department of Diagnostic RadiologyFukui-ken Saiseikai HospitalFukuiJapan
  3. 3.Department of RadiologyHyogo College of MedicineNishinomiyaJapan
  4. 4.Department of RadiologyNasu Red Cross HospitalNasuJapan
  5. 5.Department of RadiologyDaito Central HospitalDaitoJapan
  6. 6.Department of Diagnostic and Interventional RadiologyAichi Cancer Center Hospital and Research InstituteNagoyaJapan
  7. 7.Department of RadiologyNarumi HospitalAomoriJapan
  8. 8.Department of RadiologyOsaka City UniversityOsakaJapan
  9. 9.Department of Diagnostic RadiologyShizuoka Cancer CenterShizuokaJapan
  10. 10.Department of RadiologyNara Medical UniversityKashiharaJapan
  11. 11.Department of RadiologyFukuoka UniversityFukuokaJapan
  12. 12.Department of RadiologyIwate Prefectural Central HospitalMoriokaJapan
  13. 13.Department of RadiologyJikei UniversityTokyoJapan
  14. 14.Department of RadiologyToyonaka Municipal HospitalToyonakaJapan
  15. 15.Department of RadiologyHigashiosaka City General HospitalHigashiosakaJapan
  16. 16.Department of RadiologyKobe UniversityKobeJapan

Personalised recommendations